Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

240
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
240
Seizures: Classification01:13

Seizures: Classification

516
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
516
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

501
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
501
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

461
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
461

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Withdrawal and reintroduction of pharmacological treatment of epilepsy in paediatric patients. Our experience].

Revista de neurologia·2024
Same author

[Epilepsy and inborn errors of metabolism].

Revista de neurologia·2024
Same author

[Atypical growth of an intracranial lipoma].

Revista de neurologia·2022
Same author

[Abusive head trauma. A review of our experience].

Revista de neurologia·2021
Same author

[Early infantile epileptic encephalopathy due to ITPA mutation].

Revista de neurologia·2020
Same author

[Atypical presentation of early childhood epileptic encephalopathy associated with the gene KCNT1].

Revista de neurologia·2020

Related Experiment Video

Updated: Aug 12, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.7K

['Wait and see' in paediatric epilepsy. Our experience].

B Salinas-Salvador1, A Moreno-Sánchez1, G Carmen-Marcén1

  • 1HUMS. Hospital Universitario Miguel Servet, 50009 Zaragoza, España.

Revista De Neurologia
|January 27, 2023
PubMed
Summary

Pharmacological treatment for epilepsy in children should consider quality of life and neurodevelopment over seizure frequency alone. Decisions on antiepileptic drugs require parental agreement.

More Related Videos

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

25.7K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

20.4K

Related Experiment Videos

Last Updated: Aug 12, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.7K
Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

25.7K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

20.4K

Area of Science:

  • Pediatric Neurology
  • Epileptology

Context:

  • Epilepsy management in children often involves pharmacological treatment.
  • Current treatments aim to control seizures but do not offer a cure.
  • The decision to initiate treatment is complex and impacts a child's life.

Purpose:

  • To analyze the outcomes of children with non-symptomatic seizures who did not receive pharmacological treatment.
  • To evaluate the experience with untreated epilepsy in a pediatric neurology setting.

Summary:

  • A study analyzed 65 children with non-symptomatic seizures, some experiencing single or multiple events.
  • Electroencephalogram and neuroimaging findings varied, with a significant portion showing abnormalities.
  • Follow-up periods averaged 2.7 to 3.8 years, observing seizure patterns and characteristics.

Impact:

  • Treatment decisions for childhood epilepsy should prioritize quality of life and neurodevelopment.
  • Parental involvement and agreement are crucial in managing antiepileptic drug therapy.
  • This approach may lead to more individualized and less aggressive treatment strategies.